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ABSTRACT 
The objective of this study was to enhance the solubility of Methylprednisolone by choosing micronized form of drug and to enhance patient 
compliance by formulating it as dispersible tablets using quality by design (QbD) approach. Dispersible tablets of Methylprednisolone were 
developed by 23 factorial design. In this study independent variables were concentrations of MCC 102, CCS and Magnesium stearate and 
dependent variables were disintegration time, hardness and dissolution. The resulting data was fitted into Design Expert Software (Trial 
Version) and analyzed statistically using analysis of variance (ANOVA). The response surface plots were generated to determine the influence of 
concentration of MCC 102, CCS and magnesium stearate on responses. The tablets were prepared by direct compression method by choosing 
micronized form of drug and formulations were evaluated for the standard of dispersible tablets. Results showed that no significant drug-
polymer interactions in FTIR studies. According to QbD suggestion the formulation O1 (Desirability- 0.73) with MCC-38mg, CCS-3.5mg and 
magnesium stearate-2.5mg was formulated and evaluated. The disintegration time was found to be 69 seconds, hardness was found to be 64N 
and in vitro dissolution with in 30minutes. Optimized O1 formulation was within the limits of standards of dispersible tablets with increased 
water solubility and better patient compliance. Stability study on optimized O1 formulation showed that there is no significant changes during 
study period. Thus, O1 formulation was found to be stable. The study indicates that formulation of Methylprednisolone dispersible tablets by 
using QbD approach is a promising formulation development method. 
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INTRODUCTION 
The aim of the present work was to develop dispersible 
tablets of Methylprednisolone using quality risk 
management tool of the Quality by Design (QbD) approach. 
Various formulation variables involved in the development 
of dispersible tablets was identified and it was optimized for 
minimum risk level using design of experiments (DoE) tool 
for efficient reduction in the risk assessment. This reduces 
the risks involved in the development of dispersible tablets 
and yields a good quality product. The study describes 
elements of the QbD for Methylprednisolone dispersible 
tablets include: Defining quality target product profile, 
identifying critical quality attributes, establishing design 
space, control strategy. Risk assessment was done before 
applying DoE. This will reduce the risks involved in the 
development of dispersible tablets and yields a good quality 
product.1 
A problem associated with Methylprednisolone is its poor 
dissolution characteristics with water solubility of about 
120mcg/ml at 25◦C, which is a rate limiting step in the 
process of drug absorption.2 For better patient compliance 
and increasing solubility micronisation and 
superdisintegrants addition turns out to be a best option. 
Thus dispersible tablets were formulated using direct 
compression technique by dry mixture of drug having a 
reduced particle size and to enhance disintegration 
superdisintegrants are added.3 These agents are added to 
tablet formulations to promote the breakup of the tablet 
into smaller fragments in an aqueous environment thereby 
increasing the available surface area and promoting a more 
rapid release of the drug substance.4,5  
Dispersible tablets as defined in European Pharmacopoeia 
are uncoated or film coated tablets intended to be dispersed 
in water before administration giving a homogeneous 
dispersion. Typically a dispersible tablet is dispersed in 
about 5-15ml of water (e.g. in a tablespoonful or a glass of 
water) and the resulting dispersion is administered to the 
Nandhini et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):229-239 
ISSN: 2250-1177                                                                                  [230]                                                                                 CODEN (USA): JDDTAO 
patient. Dispersible tablets are required to disintegrate 
within 3min in water at 15-25◦ C. Also the dispersion 
produced from a dispersible tablet should pass through a 
sieve screen with a nominal mesh aperture of 710 microns.6 
MATERIALS AND METHOD 
Materials:  
Methylprednisolone (Micronized), Lactose Monohydrate 
(DCL 11), Microcrystalline cellulose (Avicel PH 102), 
Croscarmellose sodium, Aspartame, Trusil orange, Colloidal 
silicon dioxide and Magnesium stearate. 
Method:  
All the materials were individually dispensed and weighed. 
The sifted Methylprednisolone, Lactose spray dried DCL11, 
Microcrystalline cellulose PH (102), Croscarmellose Sodium, 
Colloidal silicon dioxide, Trusil orange, and Aspartame was 
loaded into polybag and mixed well for 10minutes. To the 
above blend sifted Magnesium stearate was added and 
mixed for 2mins. By direct compression the final lubricated 
blend is compressed in a 16 station compression machine 
(Cadmach) with 8.00mm punch size, round standard concave 
punch with plain on both the surface. 
Experimental Design 
Particle size: 
Micronized drug is chosen to increase solubility of drug. 
Particle size of micronized drug Methylprednisolone was 
found to be 1817nm using particle analyzer (Malvern). 
Compatibility study of drug and excipients using Fourier 
transform infrared spectroscopy: 
The FTIR spectra were recorded for pure drug and the 
physical mixture of drug and excipients at the scanning 
range of 4000-400 cm-1 using FTIR spectrophotometer 
(Shimadzu, Japan). FT-IR spectra of Methylprednisolone 
showed sharp characteristic peaks (Fig. 1). All the above 
characteristic peaks appeared in the spectra of physical 
mixture of drug (Fig. 2) and excipients at same wave number 
indicating no interaction between the drug and excipients.  
Initial risk assessment of the Formulation variable for 
development of Methylprednisolone dispersible tablets: 
A risk assessment of the drug substance was performed to 
evaluate the impact of CQA in product development. The 
relative risk assessment ranking system was used during 
development and it was summarized in Table 1. 7 
Quality Target Product Profile (QTPP) element analysis 
of drug product: 
The QTPP is “a prospective summary of the quality 
characteristics of a drug product that ideally will be achieved 
to ensure the desired quality, taking into account safety and 
efficacy of the drug product.”[8,9] The QTPP is an essential 
element of a QbD approach and forms the basis of design of 
the generic product. The QTPP is a quantitative substitute for 
aspects of clinical safety and efficacy. QTPP of dispersible 
tablets includes the following elements: 
 
Dosage Form Pharmacokinetics Impurities 
Route of administration Appearance Content uniformity 
Strength Identity Friability 
Weight Assay Dissolution 
 
Study of Critical Quality Attributes (CQA) of formulation 
and process:  
It was stated that the ICH working definition of CQA was: “A 
CQA is a quality attribute (a physical, chemical, biological or 
microbiological property or characteristic) that must be 
controlled (directly or indirectly) to ensure that the product 
meets its intended safety, efficacy, stability and 
performance.”10,11 CQA of dispersible tablets includes the 
following elements: 
  
Identification Weight variation Disintegration Assay 
Appearance Hardness Dissolution Product degradation 
 
Optimization of the formulation of dispersible tablets 
using 2 level Factorial Design: 
23 Factorial design (FD) formulations were developed with 
two center points. The Design Expert Software (Trial 
Version) suggested ten model formulations. Based on CQA to 
ensure safety, efficacy, stability and performance MCC, CCS 
and magnesium stearate were selected as independent 
variable and based on risk assessment study dissolution, 
disintegration time and hardness were selected as 
dependent variable for optimization study. Table 2 
summarizes an account of all the actual values and levels of 
independent variables. All other formulation variables were 
kept in\variant throughout the study. The resulting data was 
fitted into Design Expert Software (Trial Version) and 
analyzed statistically using analysis of variance (ANOVA). 
The data was also subjected to response surface 
methodology to determine the influence of concentration of 
independent variable on responses.  
Evaluation of Dispersible tablets:  
To determine weight variation, twenty tablets were selected 
randomly from each formulation and were weighed 
individually using a digital balance (Essae). The individual 
weights were compared with the average weight for 
obtaining the weight variation.12 Ten tablets from each 
formulation were selected randomly and their thickness was 
measured with a Vernier caliper (Mitutoyo). Hardness of the 
tablets was measured using a Hardness tester (Electrolab) 
and friability of a sample of twenty fast dissolving tablets 
was measured using a USP type-II Roche friabilator 
(Electrolab). Pre-weighed tablets were placed in a plastic 
chambered friabilator attached to a motor revolving at a 
speed of 25 rpm for 4 min. The tablets were then dusted, 
Nandhini et al                                                                                                        Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):229-239 
ISSN: 2250-1177                                                                                  [231]                                                                                 CODEN (USA): JDDTAO 
reweighed and percentage weight loss (friability) was 
calculated. In vitro dispersion time was determined by 
placing one tablet in a beaker containing 10 ml of water and 
time required for complete dispersion was measured as 
shown in Fig. 3. Three tablets from each formulation were 
randomly selected and dispersion time was performed.13 
Uniformity of dispersion was determined by placing two 
tablets in 100ml of water and stirred gently until completely 
dispersed.14 A smooth dispersion obtained should passes 
through sieve screen with nominal mesh aperture of 710µm 
(sieve no. 22). Dispersible tablets must disintegrate within 
3min.  
In vitro dissolution studies were performed in distilled water 
with volume of 900ml using USP apparatus Type –II (paddle) 
at temperature of 37±0.5◦C.15 The dissolution profiles of F1 
to F10 formulations are depicted in Fig. 4. 
Optimization of Methylprednisolone Dispersible Tablets 
Using 2 3 Factorial Design: 
Response 1 – Disintegration time: 
Contour plot in Fig. 5 shows that Magnesium stearate in the 
level of 2.5-3.5mg and Croscarmellose sodium in the level 
2.0-3.5mg will gives good result on disintegration time. 3D 
Response surface plot in Fig. 6 shows that disintegration 
time increase with increase in the concentration of 
magnesium stearate and disintegration time decreases by 
increasing the concentration of CCS. From ANOVA in Table 5 
the Model F-value of 26.05 implies the model is significant.  
There is only a 0.40% chance that a "Model F-Value" this 
large could occur due to noise. In this case A, B, C, BC are 
significant model terms. 
Response 2 – Hardness: 
Contour plot in Fig. 7 shows that magnesium stearate in the 
level of 2.0-4.0mg and Microcrystalline cellulose in the level 
37.5-41mg will gives good result on hardness. 3D Response 
surface plot in Fig. 8 shows that hardness increase with 
increase in the concentration of microcrystalline cellulose 
and hardness decreases by increasing the concentration of 
magnesium stearate. From ANOVA in Table 6 the Model F-
value of 729.35 implies the model is significant.  There is 
only a 0.01% chance that a "Model F-Value" this large could 
occur due to noise. Values of "Prob > F" less than 0.0500 
indicate model terms are significant. In this case A, C, AC are 
significant model terms. Values greater than 0.1000 indicate 
the model terms are not significant.  
Response 3 – In vitro Dissolution: 
Contour plot in Fig. 9 shows that magnesium stearate in the 
level of 2.0-4.0mg and croscarmellose sodium in the level 
2.5-3.5mg will gives good result on dissolution. 3D Response 
surface plot in Fig. 10 shows that dissolution increase with 
increase in the concentration of croscarmellose sodium and 
dissolution decreases by increasing the concentration of 
magnesium stearate. From ANOVA in Table 7 the Model F-
value of 165.95 implies the model is significant.  There is 
only a 0.07% chance that a "Model F-Value" this large could 
occur due to noise. Values of "Prob > F" less than 0.0500 
indicate model terms are significant.  In this case A, B, C, AC, 
BC are significant model terms. Values greater than 0.1000 
indicate the model terms are not significant.   
Formulation and Evaluation of Optimized Formulation 
O1: 
From the results of optimization study it was found that MCC 
in the concentration 37- 41mg, CCS in concentration 2.5 – 
3.5mg and magnesium stearate in concentration 2.5 – 3.5mg 
gives optimized product. So, Constrains are fixed as shown in 
Table 8 and according to QbD suggestion the formulation O1 
(Desirability- 0.73) with MCC-38mg, CCS-3.5mg and 
Magnesium stearate-2.5mg was formulated and evaluated 
for physical parameters and in vitro dissolution (Table 9). 
Assay of optimized formulation O1: (By HPLC) 
Mobile phase: 475:475:70:35:30 (butyl chloride: water-
saturated butyl chloride: THF: Methanol: glacial acetic acid); 
Wave length: 254nm. Internal standard solution (ISS): 
20mg of prednisolone was weighed and dissolved in a 3% 
v/v solution of glacial acetic acid in chloroform (0.2mg/ml of 
prednisolone). Reference solution 20mg of drug was 
weighed and dissolved in 100ml of ISS (0.2mg/ml of drug). 
Test solution: A quantity of powdered tablet containing 
10mg of drug was weighed and 50.0ml of ISS was added. 
10µl of blank, reference solution and test solution was 
injected and the peak of drug was measured.[16]  
Related substances of optimized formulation O1: (By 
HPLC)  
Mobile phase: 19:40:10 (water: THF: dimethylsulfoxide); 
Flow rate: 1.0ml/minute; Wave length: 254nm; Solvent 
mixture: 72:25:3 (water: THF: GAA) Test solution: A 
quantity of the powdered tablets containing 25mg of the 
drug was extracted and 25ml of solvent mixture was added. 
Reference solution: 0.001%w/v of Methylprednisolone in 
solvent mixture was reference solution. Reference solution 
and test solution was injected and impurities are 
measured.16 
Release Kinetics of Optimized formulation O1: 
The mechanism of release for the above formulations was 
determined by finding the R2 value for each kinetic model 
like, zero-order, first-order, higuchi, korsmeyer–peppas and 
hixon.R2 value of Higuchi model is very near to one for all 
most all the formulations than the R2 values of other kinetic 
models. Thus, it can be said that the drug release follows 
higuchi release mechanism. Further the n value of 
Korsmeyer–Peppas model for the optimized formulation was 
1.095. Therefore, the most probable mechanism of release 
was Super case II transport. 
Stability study for optimized formulation O1: 
In the present study, stability studies were carried out on 
optimized formulation under accelerated study at 40±2ºC 
and RH 75% condition for three months. The tablets were 
withdrawn at 1st and 3rd month and analyzed for physical 
characterization and drug release as shown in Table 10. 
RESULTS AND DISCUSSION 
As the material was free flowing (angle of repose value <30” 
and Carrs index <15%), tablets obtained were of uniform 
weight (due to uniform die fill). All the formulated (F1 to 
F10) tablets passed weight variation test as the % weight 
variation was within the IP limits of ±7.5% of the weight. The 
prepared formulation complies with the weight variation 
test. The maximum thickness of the formulation was found 
to be 4.0mm. The minimum thickness of the formulation was 
found to be 3.2mm. The hardness of the tablet was found to 
be 44 – 110N. The maximum friability of the formulation was 
found to be 0.96%. The minimum friability of the 
formulation was found to be 0.85%. The % friability was less 
than 1% in all the formulations ensuring that the tablets 
were mechanically stable. In vitro Disintegration time was 
found to be in the range 47 – 147 sec. All the formulations 
passes the uniformity of dispersion test. Dispersion time was 
found to be in the range 25 – 46sec for all the formulation. 
Among all the formulations F5, F6, F7 and F8 shows 100% 
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drug release within 30minutes and all the formulations 
complies the in vitro dissolution test for dispersible tablets. 
Based on CQA to ensure that the product meets its intended 
safety, efficacy, stability and performance microcrystalline 
cellulose, croscarmellose sodium and magnesium stearate 
were selected as independent variable and based on risk 
assessment study dissolution, disintegration time and 
hardness were selected as dependent variable for 
optimization study. From the results of optimization study it 
was found that MCC in the concentration 37- 41mg, CCS in 
concentration 2.5 – 3.5mg and magnesium stearate in 
concentration 2.5 – 3.5mg gives optimized product. So, 
constrains are fixed from results of study. 
According to QbD suggestion the formulation O1 
(Desirability- 0.73) with MCC-38mg, CCS-3.5mg and 
magnesium stearate-2.5mg was formulated and evaluated. 
The disintegration time was found to be 69 seconds, 
hardness was found to be 64N and in vitro dissolution with in 
30minutes. Assay for optimized O1 formulation was found to 
be 102.25% and related substances of known and unknown 
impurities was found to be 0.04% and 0.02% respectively. 
Thus optimized O1 formulation was within the limits of 
standards of dispersible tablets with increased water 
solubility and better patient compliance.  
Short-term stability studies of the above formulation 
indicated that there are no signicant changes in physical 
characterization and drug release at the end of 3 month 
period (P<0.05). Thus O1 formulation was found to be stable. 
Thus formulation of Methylprednisolone dispersible tablets 
by selecting micronized form of drug for increasing water 
solubility will reduces the problem associated with selected 
drug. Present scenario of Methylprednisolone dispersible 
tablets will finds a greater advantage due to its flexible 
design, better patient compliance, masking bitter taste of 
drug, combines the advantages of conventional dosage form, 
cost effectiveness and use of QbD approach for minimizing 
the risks involved in the development of dispersible tablets 
will yields a good quality product when compared to other 
coventional forms. Ensures better design of products with 
fewer problems in manufacturing. It is a cost effective 
method to develop generic drug production. The product can 
be consistently produced without batch to batch variations. 
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Table 1: Initial risk assessment of the Formulation variable for development of Methylprednisolone dispersible tablets. 
Drug product CQA 
 
Identification of risk 
Lactose DCL11 MCC 102 CCS 
Magnesium 
stearate 
Assay Low Low Low Low 
RS Low Low Low Medium 
Hardness Low High Medium High 
Dispersion test Low Medium High High 
Dissolution Low Medium High High 
Disintegration Low Medium High High 
 
Table 2: Optimization design summary 
Design Summary 
Study Type Factorial Design Model 3FI 
Initial Design 2 Level Factorial Runs 10 
Center Points 2 Blocks No Blocks 
 
Factor Name Units Low Actual High Actual Low Coded High Coded Mean Std. Dev. 
A MCC 102 mg 35 45 -1 1 40 4.472135955 
B CCS mg 2 4 -1 1 3 0.894427191 
C mg stearate mg 2 4 -1 1 3 0.894427191 
 
Table 3: Composition of Methylprednisolone Dispersible tablets 
Ingredients 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
mg/tab 
API 16.00 16.00 16.00 16.00 16.00 16.00 16.00 16.00 16.00 16.00 
Lactose (DCL 11) 138.5 128.5 136.5 126.5 131.5 131.5 136.5 126.5 134.5 124.5 
MCC (Avicel  102) 35.00 45.00 35.00 45.00 40.00 40.00 35.00 45.00 35.00 45.00 
CCS 2.00 2.00 2.00 2.00 3.00 3.00 4.00 4.00 4.00 4.00 
Colloidal silicon dioxide 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 
Trusil Orange 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
Aspartame 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 
Magnesium stearate 2.00 2.00 4.00 4.00 3.00 3.00 2.00 2.00 4.00 4.00 
Tablet weight 200.00mg 
 
Table 4: Evaluation of physical properties of tablet formulations 
 
Code Weight 
variation* 
(mg) 
Hardness(N
)* 
Thickness 
(mm) 
Friability 
(%) 
Uniformity of 
dispersion* 
Dispersion 
time* 
(sec) 
Dt time** 
(sec) 
F1 200.12±1.2 55±5 3.3±0.02 0.86±0.01 Passes 32±09 62±06 
F2 200.05±0.9 110±6 3.9±0.03 0.91±0.02 Passes 39±12 87±09 
F3 200.12±1.6 44±7 3.5±0.02 0.89±0.02 Passes 43±16 127±10 
F4 199.59±0.8 61±6 3.9±0.01 0.85±0.01 Passes 46±15 147±09 
F5 200.21±0.5 75±8 4.0±0.03 0.93±0.02 Passes 26±18 47±06 
F6 199.56±1.3 76±5 3.6±0.04 0.96±0.03 Passes 25±06 48±05 
F7 200.36±1.6 52±3 3.7±0.03 0.87±0.01 Passes 30±10 57±08 
F8 199.58±0.7 110±8 3.2±0.01 0.86±0.01 Passes 37±09 83±10 
F9 200.63±0.6 47±6 3.6±0.02 0.96±0.02 Passes 32±07 69±07 
F10 199.25±1.2 63±5 3.5±0.03 0.82±0.03 Passes 32±06 66±06 
*Average of 3 determinations    ±standard deviation. 
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Table 5: ANOVA for Disintegration time 
Source Sum of squares df Mean square F value p-value  
Model 7228.5 4 1807.125 26.04865 0.0040 Significant 
A-MCC 102 578 1 578 8.331532 0.0447 
 B-CCS 2738 1 2738 39.46667 0.0033 
 C-mg stearate 1800 1 1800 25.94595 0.0070 
 BC 2112.5 1 2112.5 30.45045 0.0053 
 Curvature 2528.1 1 2528.1 36.44108 0.0038 Significant 
Residual 277.5 4 69.375 
   Lack of Fit 277 3 92.33333 184.6667 0.0540 
 Pure Error 0.5 1 0.5 
   Cor Total 10034.1 9 
     
Table 6: ANOVA for Hardness 
Source Sum of squares df Mean square F value p-value   
Model 5033 3 1678 729.34783 < 0.0001 significant 
    A-MCC 102 2665 1 2665 1158.4783 < 0.0001 
     C-mg stearate 1568 1 1568 681.73913 < 0.0001 
     AC 800 1 800 347.82609 < 0.0001 
 Curvature 96.1 1 96.1 41.782609 0.0013 significant 
Residual 11.5 5 2.3 
   Lack of Fit 11 4 2.75 5.5 0.3082 
 Pure Error 0.5 1 0.5 
   Cor Total 5140 9 
     
Table 7: ANOVA for in vitro dissolution 
Source Sum of  squares df Mean square F value p-value  
Model 1728.625 5 345.725 165.948 0.0007 significant 
A-MCC 102 105.125 1 105.125 50.46 0.0057 
 B-CCS 1431.125 1 1431.125 686.94 0.0001 
 C-mg stearate 120.125 1 120.125 57.66 0.0047 
 AC 36.125 1 36.125 17.34 0.0252 
 BC 36.125 1 36.125 17.34 0.0252 
 Curvature 511.225 1 511.225 245.388 0.0006 significant 
Residual 6.25 3 2.083333333 
   Lack of Fit 6.25 2 3.125 
   Pure Error 0 1 0 
   Cor Total 2246.1 9 
     
Table 8: Optimization Constraints 
Name Goal 
Lower 
limit 
Upper limit 
Lower 
weight 
Upper 
weight 
Importance 
MCC 102 is in range 38 41 1 1 3 
CCS is in range 2.5 3.5 1 1 3 
Mg stearate is in range 2.5 3.5 1 1 1 
Disintegration time minimize 47 147 1 1 5 
Hardness is in range 44 110 1 1 1 
Dissolution maximize 59 99 1 1 5 
 
Table 9: Composition and physical parameters evaluation of Optimized O1 formulation 
 
Ingredients 
Concentration 
(mg) 
Methylprednisolone 16 
Lactose  133.5 
MCC 38 
CCS 3.5 
Colloidal SiO2 3.0 
Trusil Orange 1.0 
Aspartame 2.5 
Mg stearate 2.5 
Tablet weight 200 
 
 
Test Result 
Weight variation (mg) 200.17± 0.13 
Hardness (N) 64±1 
Thickness (mm) 3.5 ± 0.3 
Friability (%) 0.83± 0.03 
Disintegration time 
(sec) 
69±2 
Dissolution (%DR) 100% around 30 
minutes. 
Dispersion test Complies 
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 Table 10: Stability Compilation for Methylprednisolone dispersible tablets 
Test Parameters Acceptance criteria 
Initial 
results 
Condition - 40 ±20ºC & 
75±5% RH 
1st month 3rd month 
Appearance* 
White colored round shaped tablets, plain on both 
sides. 
Complies Complies Complies 
Average weight* 
(mg) 
200mg ± 7.5% 
(185.00mg – 215.00mg) 
200.17± 
0.13 
200.12± 
0.19 
199.78± 
0.21 
Hardness* (N) NLT 30N 64±1 67±2 66±2 
Disintegration Time* 
(Sec) 
NMT 3minutes 69±2 68±3 68±3 
Fineness of 
Dispersion* 
A smooth dispersion is obtained which passes 
through a sieve screen with a nominal mesh 
aperture of 710µ 
Complies Complies Complies 
Dissolution* NLT 70% of label claim 100% 100% 100% 
*Average of 3 determinations    ±standard deviation. 
 
 
Figure 1:  IR spectra of Methylprednisolone 
 
Figure 2: IR spectra of Physical mixture 
 
  
Figure 3: Dispersion test for Methylprednisolone dispersible tablets  
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Figure 4: In vitro Drug Release Profile (F1-F5) 
 
Figure 5: Contour plot showing the effect of amount of CCS and Magnesium stearate on Disintegration time. 
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Figure 6: 3D Response Surface Plot Showing Effect of CCS and Magnesium stearate on Disintegration time
 
Figure 7: Contour plot showing the effect of amount of MCC and Magnesium stearate on Hardness
 
Fig. 8: 3D Response Surface Plot Showing Effect of MCC and Magnesium stearate on Hardness 
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Figure 9: Contour plot showing the effect of amount of CCS and Magnesium stearate on Dissolution 
  
Fig Fig. 10: 3D Response Surface Plot Showing Effect of CCS and Magnesium stearate on Dissolution 
 
 
Figure 12: Release kinetic mechanism of optimized formulation O1 
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Fig. 13: Sample Graph of Methylprednisolone for assay 
 
 
Fig. 14: Sample Graph of Methylprednisolone for Related substances 
 
 
Figure 15: In vitro drug release study of optimized formulation before and after stability 
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